World Sleep Industry ENCYCLOPEDIA

Wakefulness-Promoting Prescription Drugs

2.1.1

Definition, included medicines, and classification boundary

Wakefulness-promoting prescription drugs are medicines used to improve excessive sleepiness caused by specified diseases or sleep-wake disorders and to increase the ability to remain awake. Representative ingredients include modafinil, armodafinil, solriamfetol, and pitolisant. In selected settings such as narcolepsy, a prescriber may also evaluate methylphenidate, dextroamphetamine, or other traditional central nervous system stimulants. These medicines do not share one target, indication, controlled status, or risk profile, so “wake-promoting drug” is a functional clinical grouping rather than an interchangeable pharmacologic class.

This entry separates them from caffeinated drinks, dietary supplements, nonprescription alertness products, routine treatment of attention-deficit/hyperactivity disorder, and medicines directed at nighttime features of narcolepsy. Promoting wakefulness is also different from obtaining adequate sleep, correcting circadian timing, or treating upper-airway collapse in obstructive sleep apnea. A drug may reduce perceived sleepiness or improve a test result without restoring normal alertness, and it must not be used to support chronic sleep deprivation, drowsy driving, or prolonged work.

Authorized uses, regional differences, and evidence limits

In the United States, labels for modafinil and armodafinil include excessive sleepiness associated with adult narcolepsy, obstructive sleep apnea, or shift work disorder. Solriamfetol improves wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. The United States pitolisant label covers excessive daytime sleepiness or cataplexy in patients six years and older with narcolepsy. Exact age, symptom, product, and jurisdiction must be checked separately; authorization for one ingredient or region cannot be generalized to all products.

Regional differences are substantial. The European Union restricted modafinil to sleepiness associated with narcolepsy and removed former uses involving obstructive sleep apnea, shift work disorder, and idiopathic hypersomnia. Professional guidelines may recommend medicines for narcolepsy, idiopathic hypersomnia, or selected secondary hypersomnolence based on evidence, but a guideline recommendation does not automatically create local marketing authorization. Off-label use requires documentation of diagnosis, evidence, uncertainty, alternatives, and informed discussion. Commercial communication must not recast a conditional recommendation as a universally authorized use.

Pretreatment diagnosis, underlying care, and goals

Before prescribing, distinguish sleepiness from fatigue and assess sleep duration, schedule and shift work, medicines and substances, depression and other psychiatric conditions, thyroid disease, neurologic disease, and other contributors. Complete appropriate evaluation for narcolepsy, idiopathic hypersomnia, obstructive sleep apnea, or a circadian rhythm disorder when indicated. Baseline review includes blood pressure, pulse and rhythm, cardiovascular or cerebrovascular disease, hepatic and renal function, psychosis or bipolar history, serious rash or allergy history, pregnancy and lactation, and risk of medicine misuse.

In obstructive sleep apnea, a wake-promoting drug addresses residual sleepiness and does not relieve upper-airway obstruction. When positive airway pressure or another airway treatment is appropriate, it should be adequately implemented before wake-promoting treatment and adherence, leak, residual respiratory events, and sleep duration should continue to be reviewed. Shift work disorder also calls for attention to scheduling, sleep opportunity, and light exposure. Goals should include measurable sleepiness improvement, daily and occupational function, accident risk, and quality of life rather than merely extending time awake.

Pharmacology, product differences, and interactions

The complete wake-promoting mechanisms of modafinil and armodafinil remain uncertain but involve pathways including dopamine transporter activity. They are related ingredients, not products that can be converted directly by tablet count. Solriamfetol inhibits dopamine and norepinephrine reuptake, although its clinical effect should not be reduced to a single-transmitter explanation. Pitolisant is a histamine H3 receptor antagonist or inverse agonist that enhances central histaminergic signaling. Traditional stimulants have different catecholamine actions and a more prominent misuse profile.

Every prescription medicine, nonprescription product, supplement, nicotine, caffeine, and alcohol use belongs in the interaction review. Solriamfetol has strict combination and washout restrictions with monoamine oxidase inhibitors, and medicines that raise blood pressure, pulse, or dopaminergic activity may add risk. Modafinil, armodafinil, and pitolisant can alter exposure to other medicines through CYP pathways and may reduce hormonal contraceptive effectiveness; alternative contraception and its duration must follow the specific label. Pitolisant also requires review of QT-prolonging medicines and centrally acting H1 antihistamines. Hepatic or renal function, CYP2D6 metabolizer status, and formulation affect management for some products, so independent cross-product conversion is unsafe.

Persistent sleepiness, driving, and response monitoring

Residual sleepiness can remain despite treatment, and a person may underestimate drowsiness during monotonous or prolonged tasks. At treatment initiation, after regimen changes, and at each review, clinicians should ask directly about driving, commuting, machinery, work at height, caregiving, and long meetings rather than only asking whether energy feels better. Driving and other hazardous activity should be avoided until alertness is known to be adequate for the task. Medicine cannot reverse all impairment caused by insufficient sleep, alcohol, sedatives, or circadian misalignment.

Response can be assessed with a validated subjective scale, unintended dozing, unplanned naps, work or study performance, objective wakefulness testing when appropriate, and observations from family or colleagues. A transient stimulant sensation, faster pulse, or insomnia is not evidence of effective treatment. Persistent or abruptly worse sleepiness calls for reassessment of sleep opportunity, control of the underlying disorder, adherence, interactions, and new illness rather than self-directed escalation. Cataplexy, sleep paralysis, or hallucinations may also require goals distinct from daytime sleepiness.

Ingredient-specific serious risks and controlled status

Modafinil and armodafinil can cause headache, nausea, anxiety, and insomnia. More serious warnings include severe rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, multiorgan hypersensitivity, angioedema, psychiatric symptoms, and cardiovascular events. Rash, mucosal injury, facial swelling, breathing difficulty, fever with organ symptoms, mania, hallucinations, suicidal thoughts, chest pain, fainting, or a marked rhythm abnormality requires immediate cessation of hazardous activity and urgent contact with a healthcare professional; a life-threatening presentation requires emergency help first.

Solriamfetol can increase blood pressure and heart rate and can cause anxiety, irritability, or insomnia; declining renal function raises exposure and related risk. Pitolisant can prolong the QT interval, requiring special review with hepatic or renal impairment, electrolyte disturbance, bradycardia, or another QT-prolonging medicine. It can also cause insomnia, headache, nausea, anxiety, or hallucinations. Controlled status varies by ingredient and country. Modafinil, armodafinil, and solriamfetol are Schedule IV in the United States, traditional amphetamines and methylphenidate are more tightly controlled, while pitolisant is not federally controlled in the United States. Noncontrolled does not mean risk-free; every product must be protected from misuse, sharing, and resale.

Review, discontinuation, storage, and life-cycle governance

Review should cover sleepiness and functional goals, driving and accidents, nighttime sleep quality, blood pressure and pulse, weight and appetite, skin and allergic reactions, mood and behavior, cardiac electrical risk, hepatic and renal function, underlying treatment, and signs of misuse. Long-term prescribing should not continue by refill inertia alone. If net benefit is inadequate, risk rises, or the diagnosis changes, the prescriber should plan adjustment, switching, or discontinuation. Abrupt change to a traditional stimulant or another regularly used medicine can produce rebound sleepiness, mood change, or other withdrawal effects, so patients should not stop or escalate on their own.

Keep medicines in their original containers, store them according to the label, and prevent access by children or other people. Controlled medicines must follow local rules for security, refills, travel, and disposal. Return unwanted supplies through local take-back systems or follow pharmacist guidance. Clinical records, procurement, and commercial communication should state the ingredient, indication, region, age range, and material monitoring and must not claim “replaces sleep,” “makes driving safe,” “cures sleep apnea,” or “nonstimulant means no risk.” Medication belongs within life-cycle care based on an established diagnosis, effective underlying treatment, and continuing reassessment.